[Treatment with mexiletine. Clinical and pharmacokinetic studies].
Pharmacokinetics of the antiarrhythmic agent mexiletine were found to be highly variable. Ineffective or toxic doses can be avoided by monitoring mexiletine concentrations in patients plasma. However, the success of antiarrhythmic therapy is mainly determined by the severity of the underlying disease. Therefore, the efficacy of treatment with mexiletine should be controlled by Holter monitoring.
Breithaupt
H
H
Medizinische Klinik der Universität Giessen.
Schmidt
A
A
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005117:Cardiac Complexes, Premature / Q000097:blood / Q000188:drug therapy*; D004562:Electrocardiography; D006801:Humans; D007262:Infusions, Intravenous; D008657:Metabolic Clearance Rate; D008801:Mexiletine / Q000493:pharmacokinetics / Q000506:poisoning / Q000627:therapeutic use*; D008875:Middle Aged; D014693:Ventricular Fibrillation / Q000097:blood / Q000188:drug therapy*
D008801:Mexiletine
Behandlung mit Mexiletin. Klinische und pharmakokinetische Untersuchungen.